Liraglutide, a Glucagon-Like Peptide-1 Analog, Increased Insulin Sensitivity Assessed by Hyperinsulinemic-Euglycemic Clamp Examination in Patients with Uncontrolled Type 2 Diabetes Mellitus

Figure 2

Changes in glucose infusion rate in euglycemic-hyperinsulinemic clamp after the 4-week intensive insulin-therapy and liraglutide-therapy. Bar graphs represent the amount of change in glucose infusion rate (GIR) as the mean and standard error of mean in patients with intensive insulin-therapy () and liraglutide-therapy (). Change in GIR (mg/kg/min) = (GIR after 4 weeks of therapy) − (GIR at admission). The intergroup comparisons of the changes in GIR values in liraglutide-therapy were significantly higher than those in intensive insulin-therapy (unpaired -test, ).